Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EVGNBullishCorporate Developmentsnews

High materiality9/10

Evogene Advances AI-Driven Chemistry With Leaner Ops and More Collaborations

Aug 18, 2026, 8:09 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The update shows meaningful cost reductions, a stronger balance sheet, and expanded AI-driven discovery capacity; multiple collaborations provide optional upside and potential future revenue streams, supporting a re-rating versus prior guidance.

AI summary

What happened, with direct paths to the underlying reporting

Evogene reports progress from its 2025 strategic transformation into a lean, AI-driven computational chemistry company with momentum in pharma and agriculture. It highlights six active collaborations, expansion of ChemPass AI to 110 billion molecules, and autonomous AI Agents, while guiding 2026 cash burn to $8.5–$9.5 million and a cash balance of about $9.3 million as of 6/30/2026. Near-term catalysts include collaboration milestones and internal programs advancing toward preclinical development.

Evogene accelerates AI-driven computational chemistry with momentum in pharma and ag.
2026 cash burn guidance: $8.5–$9.5M; 2025 burn was $14.4M.
Q2 2026 net loss $1.8M; H1 2026 revenue $0.7M; cash $9.3M.
Pharma collaborations rise to six; two programs reached Hit Identification in ChemPass AI.
ChemPass AI expands to 110B molecules; autonomous AI Agents; Google Cloud tie; APP predictor.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.